Dual blockage by combination of anti-CTLA-4 and anti-PD-1 treatments demonstrated better efficiency in the 4T1 triple negative breast cancer model when compared to monotherapy. The gene discussed is CTLA4; the disease is triple-negative breast carcinoma.